??Narrative Review: What is new in COVID-19?
??Published in Intensive Care Medicine
- This article discusses the need for more clinical trials and research on COVID-19 in low- and middle-income countries.
- It highlights the limited number of studies conducted in these settings and emphasizes the importance of collecting long-term data on treatment effectiveness.
- The article also mentions ongoing adaptive platform trials and the opportunities they provide for learning about treatment heterogeneity and subgroup effects.
- Hallmark of COVID-19 research was rapid generation of evidence for therapeutics through Adaptive COVID-19 Treatment Trial (ACTT) platform.
- Research is required for awake probing and newer respiratory support like HFNC for the managment of acute hypoxemic respiratory failure
- Clinical guidelines on COVID-19 should abreast to the ongoing research and changing evidence.
- Lession and opportunities: Adaptive platform trials offer learning opportunities for understanding treatment heterogeneity and subgroup effects. More eveidence is required from low- and middle-income countries. However, collaborative research can reduce inequality in resources and
??Limitations: The author acknowledges the advances made during the pandemic but also highlights the limitations and the need for improvement.
